PharmaCyte Biotech, Inc. (PMCB)

2.1200 0.0000 (0.00%) At close: 04:00PM EDT

PharmaCyte Biotech, Inc.

3960 Howard Hughes Parkway
Suite 500
Las Vegas, NV 89169
United States
917 595 2850
https://pharmacyte.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 2

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Joshua N. Silverman	Interim CEO, President & Director	197.92k	N/A	1970
Mr. Carlos A. Trujillo CPA, CPA	Chief Financial Officer	380k	N/A	1958
Dr. Jose L. Iglesias M.D.	Consulting Chief Medical Officer	N/A	N/A	1957
Dr. Hans-Peter Hammes	Member of Medical & Scientific Advisory Board and Consultant	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Corporate Governance

PharmaCyte Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.